| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
24013 |
| Drug |
Pembrolizumab |
| Brand |
Keytruda® |
| Indication |
Pembrolizumab, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non-small cell lung carcinoma (NSCLC) at high risk of recurrence in adults. |
| Rapid review commissioned |
22/04/2024 |
| Rapid review completed |
16/05/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment of resectable NSCLC, compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
29/05/2024 |
| Pre-submission consultation with Applicant |
02/07/2024 |
